n. 13, October 2018

I'm an image

Survey on osteoporosis and fracture risk in advanced chronic kidney disease and following renal transplantation

Dear colleague,

As you’re probably aware, the fracture burden is excessively high in patients with chronic kidney disease (CKD). Fracture risk ”dose dependently” increases along the progression of kidney failure to become about fourfold higher in patients with end stage renal disease than in age and gender matched healthy controls. It further increases following renal transplantation, at least in the early posttransplant period. According to the KDIGO 2017 Clinical Practice Guideline Update for the diagnosis, evaluation, prevention, and treatment of CKD-MBD, bone mineral density testing is recommended if a therapeutic decision is being considered.

While most treatments for osteoporosis work equally well in patients with CKD stage 1-3 and should be used as indicated based on data from the general population, evidence  gaps in the optimal strategy for diagnosis, prognostication, and treatment remain for more advanced stages of CKD and post-transplant. The current survey aims to identify areas of uncertainty with regard to the diagnosis and treatment of osteoporosis in patients with advanced CKD and posttransplant.


This survey is endorsed by the ERA-EDTA working group on CKD-MBD and by the International Osteoporosis Foundation (IOF). All members of the ERA-EDTA CKD-MBD working group and the IOF committee of scientific advisors are invited to participate to the survey. Since the approach to osteoporosis may be different in patients with advanced CKD and posttransplant, we split the survey in 2 parts: part 1 deals with adult patients with advanced CKD and part 2 reiterates some statements for whom the answer may be different in renal transplant recipients. The completion of the survey requires approximately 15 minutes of your time. Results of the survey will exclusively be used to be discussed in a consensus meeting including both nephrologists and bone heads. The report of this consensus meeting, which may serve as a blueprint for further research, will be presented for open discussion at the forthcoming 2nd European Renal Osteodystrophy (EUROD) meeting in Leuven (Belgium), January 18, 2019 (click here to see the programme). You have just recently received a formal invitation to join this CME shortly.


Click here to participate in the survey: your help is very much appreciated!


We hope to see you all in Leuven (Belgium), January 18, 2019.


Also on behalf of M Haarhaus, J Cannata-Andia, J Cunningham, S  Ferrari, K Javaid, D Prieto-Alhambra and PU Torres


Pieter Evenepoel

Chairman EUROD, an initiative of the CKD-MBD -  An official ERA-EDTA Working Group

Web Site E-Mail Facebook Twitter Google+ LinkedIn Instagram YouTube Vimeo

You are receiving this email since you are a member of ERA-EDTA/CKD-MBD working group/ IOF committee of scientific advisors. If you no longer wish to receive these communications, send and email to ckd-mbd@era-edta.org and specify REMOVE ME in the subject of the email.